{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:18:59Z","timestamp":1790893139435,"version":"4.1.0"},"reference-count":112,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B\u2010cell chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the United States, and its diagnosis can have many dermatologic implications. For one, the cutaneous manifestations of CLL include several entities, most notably leukemia cutis, eosinophilic dermatosis of hematologic malignancy, and a heightened risk of skin infections. Additionally, CLL patients are at an increased risk of secondary malignancies, most commonly of the skin. Furthermore, a number of commonly utilized treatments for CLL have cutaneous implications which should be considered in the interdisciplinary management of CLL patients. In this review, we will provide an update on the diverse cutaneous manifestations of CLL and CLL\u2010directed therapies in order to help guide dermatologic management of this increasingly prevalent patient population.<\/jats:p>","DOI":"10.1111\/ijd.15629","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T09:57:53Z","timestamp":1620295073000},"page":"519-531","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chronic lymphocytic leukemia and the skin: implications for the dermatologist"],"prefix":"10.1111","volume":"61","author":[{"given":"Lauren J.","family":"Fried","sequence":"first","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York City NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maressa C.","family":"Criscito","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York City NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York City NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam K.","family":"Pomeranz","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine New York City NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601137336"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.06.003"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2004.00489.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05982.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2012.01906.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.5070\/D3984767VV"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2178"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1994.tb01173.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102016\u2010215108"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199608000-00009"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.047"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1309\/WYACYWF6NGM3WBRT"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540300700110"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07129.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2003.00167.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2005.00377.x"},{"key":"e_1_2_10_19_1","first-page":"E23","article-title":"Chronic lymphocytic leukemia and infiltrates seen during excision of nonmelanoma skin cancer","volume":"103","author":"Maxfield L","year":"2019","journal-title":"Cutis"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12015"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1993.tb02184.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.048"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.026"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13389"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07576.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1407645"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.013"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.12.004"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-04220-6_11"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.005"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219856422"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy168"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13001"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832154"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-818286"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2019.12.005"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.031"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.755178"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1267352"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2015.10.035"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.078"},{"key":"e_1_2_10_46_1","unstructured":"Shingles: Vaccines [CDC Factsheet].CDCgov.2019. Available at:https:\/\/www.cdc.gov\/shingles\/vaccination.html. Published July 01 2019. Accessed November 8 2019."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.8.985"},{"key":"e_1_2_10_48_1","first-page":"571","article-title":"Skin cancer in patients with chronic lymphocytic leukemia and non\u2010Hodgkin lymphoma","volume":"10","author":"Onajin O","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1620941"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.6249"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9605"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1665669"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4725.2003.29034.x"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31006"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2018.07.009"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.10.028"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.018"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000798"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.09.030"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2002.00665.x"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv294"},{"key":"e_1_2_10_62_1","unstructured":"Chronic Lymphocytic Leukemia Treatment (PDQ\u00ae): Health Professional Version.National Cancer Institute;2019. Available from:https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK66035\/."},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23775"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.02.001"},{"key":"e_1_2_10_65_1","unstructured":"Janssen Biotech Inc.Imbruvica (ibrutinib) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210563s000lbl.pdf. Revised February 2018. Accessed April 14 2020."},{"key":"e_1_2_10_66_1","unstructured":"AstraZeneca Pharmaceuticals\u2009LP.CALQUENCE (acalabrutinib) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf. Revised October 2017. Accessed April 14 2020."},{"key":"e_1_2_10_67_1","doi-asserted-by":"crossref","unstructured":"BondDA.Second cancer incidence in CLL patients receiving BTK inhibitors. 2019 ASCO Annual Meeting; June 3 2019.Chicago Illinois;2019.","DOI":"10.1097\/01.HS9.0000562880.65614.d6"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S219570"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0225"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.018"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14302"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.12.954"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0457"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00535-x"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1877"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2522"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630947"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.07.033"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1734557"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.5070\/D34NS1K655"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf350"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0169"},{"key":"e_1_2_10_87_1","first-page":"717","article-title":"Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia","volume":"18","author":"Schierl M","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.06.007"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63504-3"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8"},{"key":"e_1_2_10_91_1","unstructured":"Arzerra (ofatumumab) [package insert].East Hanover NJ:Novartis Pharmaceuticals Corporation;2016."},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12800"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1985"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70398-6"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(73)90138-2"},{"key":"e_1_2_10_97_1","first-page":"102","article-title":"Chronic lymphocytic leukaemia manifestating as exfoliative dermatitis","volume":"61","author":"Dhir R","year":"1995","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.05916-3"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1980.00330220077028"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3611"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2944-7"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502986"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000980"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000862"},{"key":"e_1_2_10_105_1","unstructured":"Verastem Inc.COPIKTRA (duvelisib) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211155s000lbl.pdf. Revised September 2018. Accessed April 26 2020."},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000032"},{"key":"e_1_2_10_107_1","unstructured":"Teva Pharmaceuticals USA Inc.TREANDA (bendamustine) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022249s014lbl.pdf. Revised August 2013. Accessed April 26 2020."},{"key":"e_1_2_10_108_1","unstructured":"GlaxoSmithKline.LEUKERAN (chlorambucil) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/010669s032lbl.pdf. Revised 2006. Accessed April 26 2020."},{"key":"e_1_2_10_109_1","unstructured":"Baxter Healthcare Corporation.Cyclophosphamide [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012141s090 012142s112lbl.pdf. Revised May 2013. Accessed April 26 2020."},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12406"},{"key":"e_1_2_10_111_1","unstructured":"Bayer Pharmaceuticals.Fludara (Fludarabine) [package insert].U.S. Food and Drug Administration website. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020038s032lbl.pdf. Revised July 2008."},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.00917.x"},{"key":"e_1_2_10_113_1","unstructured":"Pfizer Inc.Nipent (Pentostatin) [package insert]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020122s015lbl.pdf. Revised October 2019. Accessed April 18 2020."}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.15629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.15629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:39:14Z","timestamp":1700210354000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.15629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/ijd.15629"],"URL":"https:\/\/doi.org\/10.1111\/ijd.15629","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"2020-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}